Efficacy and safety of Apixaban in the treatment of cerebral venous sinus thrombosis: a multi-center study.

Autor:	Simaan N; Department of Neurology, Ziv Medical Center, Safed, Israel.; The Azrieli Faculty of Medicine, Safed Bar Ilan University, Safed, Israel., Metanis I; Hadassah Departments of Neurology, Hebrew University Medical Center, Jerusalem, Israel., Honig A; Hadassah Departments of Neurology, Hebrew University Medical Center, Jerusalem, Israel., Hallevi H; Department of Neurology and Stroke, Tel-Aviv Sourasky Medical Center, Tel-Aviv, Israel.; Faculty of Medicine and Sagol School of Neuroscience, Tel-Aviv University, Tel-Aviv, Israel., Filioglo A; Hadassah Departments of Neurology, Hebrew University Medical Center, Jerusalem, Israel., Mendel R; Department of Neurology, Assuta Ashdod Medical Center, Ashdod, Israel., Barnea R; Department of Neurology, Rabin Medical Center, Petah Tikva, Israel., Naftali J; Department of Neurology, Rabin Medical Center, Petah Tikva, Israel., Auriel E; Department of Neurology, Rabin Medical Center, Petah Tikva, Israel., Aladdin S; Departments of Neurology, Sheba Medical Center, Ramat Gan, Israel., Orion D; Departments of Neurology, Sheba Medical Center, Ramat Gan, Israel., Dally N; The Azrieli Faculty of Medicine, Safed Bar Ilan University, Safed, Israel.; Department of Hematology, Ziv Medical Center, Safed, Israel., Leker RR; Hadassah Departments of Neurology, Hebrew University Medical Center, Jerusalem, Israel., Molad J; Department of Neurology and Stroke, Tel-Aviv Sourasky Medical Center, Tel-Aviv, Israel.
Jazyk:	angličtina
Zdroj:	Frontiers in neurology [Front Neurol] 2024 May 16; Vol. 15, pp. 1404099. Date of Electronic Publication: 2024 May 16 (Print Publication: 2024).
DOI:	10.3389/fneur.2024.1404099
Abstrakt:	Background: Information regarding the safety and efficacy of specific direct oral anticoagulants (DOAC) in the treatment of cerebral sinus and venous thrombosis (CSVT) is scarce. Apixaban is one of the most frequently prescribed DOACs. Therefore, we aimed to compare the safety and efficacy of Apixaban with those of vitamin k antagonists (VKA) in patients with CSVT. Methods: Prospective CSVT databases from seven academic medical centers were retrospectively analyzed. Patients treated with Apixaban were compared to those treated with VKA. Data on demographics, clinical presentations, risk factors, radiological and outcome parameters were studied. Results: Overall, 403 patients were included in the analysis. Of them, 48 (12%) were treated with Apixaban, and 355 (88%) were treated with VKA. Rates of coagulopathies were significantly higher in the VKA-treated patients but no other differences between the groups were found in baseline characteristics and underlying etiology. No significant differences were found between groups in efficacy or safety parameters including the rates of recanalization, favorable outcomes, one-year mortality, seizures, intracranial hemorrhage or CSVT recurrences. Conclusion: Our data suggests that Apixaban may be safe and effective for patients with CSVT. These results should be tested in prospective randomized clinical studies. Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. (Copyright © 2024 Simaan, Metanis, Honig, Hallevi, Filioglo, Mendel, Barnea, Naftali, Auriel, Aladdin, Orion, Dally, Leker and Molad.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu